CP v2

Category: Psychology

  • Ozempic and other GLP-1 drugs tied to lower depression and anxiety in large Swedish study, raising new questions about mental health benefits

    Ozempic and other GLP-1 drugs tied to lower depression and anxiety in large Swedish study, raising new questions about mental health benefits

    Popular GLP-1 medicines used for type 2 diabetes and weight loss, including Ozempic and Wegovy, may be linked to improved mental health outcomes, according to a large new analysis of Swedish health data. Researchers tracked changes in psychiatric care and work absence during periods when patients were using these drugs.

    The study, led by scientists from the University of Eastern Finland, Karolinska Institutet and Griffith University, examined national register data spanning 2009 to 2022. Nearly 100 000 people were included, with more than 20 000 having used a GLP-1 receptor agonist at some point during follow-up.

    What the study found

    Across the dataset, GLP-1 use was associated with fewer psychiatric hospital visits and fewer days of sickness absence related to mental health conditions. The strongest associations were reported for semaglutide, the active ingredient in Ozempic and Wegovy.

    During periods of semaglutide use, psychiatric hospital care and sickness absence were reported as 42% lower than during periods off treatment. The analysis also linked semaglutide exposure with a 44% lower risk of depression and a 38% lower risk of anxiety disorders.

    Signals beyond mood and anxiety

    The researchers also reported a lower rate of hospital care and work absence tied to substance use disorders during semaglutide treatment periods, with a reduction of 47%. They additionally found an association between GLP-1 receptor agonist use and reduced suicidal behavior, though the study design cannot determine causality.

    One author, Professor Mark Taylor of Griffith University, said the direction of the results aligned with earlier register-based research suggesting GLP-1 use may be associated with a reduced risk of alcohol use disorder. Because alcohol problems can worsen mood symptoms, the team said this could be one pathway behind the observed patterns.

    Why it may happen, and what it means

    Experts caution that registry studies can show links but cannot prove the drugs directly prevent depression or anxiety, since unmeasured factors could influence who starts or stays on treatment. Researchers said potential explanations range from improved blood sugar control and weight loss to reduced alcohol use and better quality of life.

    They also pointed to possible direct effects on the brain, including changes in reward-related pathways, as a hypothesis that needs targeted clinical research. The findings were published in The Lancet Psychiatry, adding weight to an ongoing debate as regulators and clinicians continue to watch for both potential benefits and risks affecting mental health.

  • A simple blood test could spot depression risk early by tracking immune cell aging

    A simple blood test could spot depression risk early by tracking immune cell aging

    Researchers are testing whether a routine blood sample could help flag depression earlier, using measures of biological aging in specific immune cells. The work adds to a growing push for objective biomarkers that could complement symptom-based mental health screening.

    The study, published in The Journals of Gerontology: Series A, examined epigenetic changes that act like molecular timestamps on DNA. These so-called epigenetic clocks estimate biological age, which can advance faster than chronological age under stress, illness, or other factors.

    Why depression has been hard to test

    Depression is typically diagnosed through clinical interviews and questionnaires, not lab confirmation, partly because the condition can look very different across patients. Some people primarily experience somatic symptoms such as sleep and appetite changes, while others struggle most with mood and cognition, including hopelessness and loss of pleasure.

    That variability can complicate detection, especially when physical symptoms overlap with other chronic conditions. Clinicians may order bloodwork to rule out medical causes, but there is still no widely accepted biological test that can confirm depression on its own.

    Monocytes emerge as a key signal

    The research analyzed data from 440 women, including 261 living with HIV and 179 without HIV, drawing on the long-running Women’s Interagency HIV Study. Depression symptoms were assessed using the Center for Epidemiologic Studies Depression Scale, a 20-item tool that captures both somatic and non-somatic features.

    Blood samples were used to calculate epigenetic aging in two ways: a broad measure across multiple cell types and a monocyte-focused clock. Monocytes are white blood cells involved in immune responses and inflammation, processes increasingly studied for their links to mental health.

    The monocyte-specific aging measure tracked most strongly with non-somatic depression symptoms such as anhedonia, hopelessness, and a sense of failure, in women with and without HIV. By contrast, the broader multi-tissue aging measure did not show the same relationship, suggesting the signal may be cell-type specific.

    What this could change in care

    The authors caution that the findings are not yet ready for clinical use and do not mean a single blood draw can diagnose depression today. Larger studies, replication in different populations, and clearer thresholds would be needed before a test could be validated for real-world screening.

    Still, the results point to a possible path toward earlier, more precise detection, particularly for people whose physical symptoms might be attributed to other illnesses. If confirmed, immune-cell epigenetic measures could also support more personalized care by helping researchers distinguish depression subtypes and refine treatment matching.

  • Creatine research shifts beyond the gym: What studies suggest about brain health, mood and aging

    Creatine research shifts beyond the gym: What studies suggest about brain health, mood and aging

    Creatine has long been associated with strength and sprint performance, but a growing body of research is examining what it may do beyond muscle gains. Scientists are increasingly focused on its role in cellular energy, including in the brain, where energy demand is high.

    The compound is made in the body from amino acids and stored mainly in skeletal muscle, with smaller amounts in organs such as the brain and heart. In cells it supports the rapid recycling of ATP, the core energy molecule, which helps explain why supplementation can aid short, high-intensity efforts.

    Why creatine matters in the brain

    Because brain tissue depends on steady energy supply, researchers are studying whether creatine can support cognition under stress, sleep loss or aging. Some studies have reported improvements in tasks linked to memory and processing speed, especially in people likely to start with lower creatine stores.

    Interest is also expanding into mental health and neurological disease, including depression and Parkinson’s disease, where energy metabolism and inflammation may play a role. Evidence remains mixed and condition-specific, and experts stress that early signals do not yet translate into routine medical use.

    What dosing research typically uses

    The most studied form is creatine monohydrate, commonly taken either as a short loading phase of about 20 g daily for 5 to 7 days or as a steady daily dose around 3 to 5 g. Research suggests both approaches can raise muscle stores, with loading working faster and lower daily dosing reaching saturation over several weeks.

    Absorption and retention vary between individuals, partly because tissues have a storage ceiling and excess is converted to creatinine and excreted. Some evidence indicates taking creatine with carbohydrates can increase uptake, though the real-world impact differs by person and diet.

    Safety, limits and who should ask first

    Large reviews and position statements have generally found creatine to be safe for healthy adults when used as studied, and it is not a steroid or hormone. The most common issues are practical rather than dangerous, such as water retention or stomach upset at higher single doses.

    Clinicians still advise caution for people with kidney disease or those advised to limit protein-related metabolites, since creatinine levels can rise with supplementation and complicate lab interpretation. Researchers emphasize that creatine is not a cure-all and works best as a targeted aid alongside training, nutrition and medical guidance when needed.

  • Deep Sleep and Growth Hormone: UC Berkeley Study Maps Brain Circuit That Links Nighttime Repair to Wakefulness

    Deep Sleep and Growth Hormone: UC Berkeley Study Maps Brain Circuit That Links Nighttime Repair to Wakefulness

    Deep non-REM sleep has long been tied to the body’s biggest overnight growth hormone surge, a rhythm linked to tissue repair, muscle maintenance and metabolic health. A new study from researchers at the University of California, Berkeley offers a clearer explanation of how the brain coordinates that hormone release during sleep.

    In work published in Cell, the team traced a neural circuit in the hypothalamus that helps control when growth hormone is released and how that signal is kept in balance. The findings come as sleep disruption is increasingly associated in research with higher risks for weight gain, insulin resistance and cardiovascular disease.

    A circuit with two hormone controls

    The study focuses on two hypothalamic signals that act as opposing levers: growth hormone releasing hormone, which promotes growth hormone output, and somatostatin, which suppresses it. By mapping how these systems behave across sleep stages, researchers aimed to explain why fragmented or reduced deep sleep can blunt growth hormone release.

    Using mice, the researchers recorded neural activity and manipulated specific neurons to observe how these signals shift across REM and non-REM sleep. They reported that the two hormones follow distinct patterns depending on the sleep stage, producing different growth hormone dynamics over the night.

    How growth hormone feeds back

    The team also describes a feedback loop connecting growth hormone signaling to the locus coeruleus, a brainstem hub involved in alertness and attention. As growth hormone levels build, the circuit can influence arousal, suggesting the hormone is not only an output of sleep but also a contributor to sleep-wake regulation.

    Because the locus coeruleus is implicated in a range of neurological and psychiatric conditions, the authors say the circuit-level map could help guide future work on sleep disorders and diseases where arousal systems are disrupted. However, the research was conducted in mice, and any clinical applications would require further validation in humans.

    Why the findings matter

    Growth hormone is best known for its role in childhood and adolescent growth, but it also supports adult physiology by influencing body composition and how the body handles sugar and fat. That is why chronically poor sleep, particularly reduced deep sleep, has been linked in broader research to metabolic problems over time.

    The researchers argue that identifying the wiring behind growth hormone regulation may eventually inform therapies that target specific nodes in the sleep-hormone system. For now, the study adds detailed biological context to a familiar health message: sleep quality can shape key hormonal processes, not just next-day energy.

    The work was supported by the Howard Hughes Medical Institute and the Pivotal Life Sciences Chancellor’s Chair fund, and included collaborators from UC Berkeley and Stanford University. The authors emphasize that the new circuit map is a foundation for future studies on how sleep architecture and hormones interact in health and disease.

  • Astrocytes move into the spotlight: New Nature study links overlooked brain cells to fear memories and PTSD pathways

    Astrocytes move into the spotlight: New Nature study links overlooked brain cells to fear memories and PTSD pathways

    Brain research is increasingly challenging the long-held idea that neurons alone drive fear and trauma responses. A new study in Nature points to astrocytes, star-shaped support cells, as active players in how fear memories are formed, recalled and reduced.

    Astrocytes are widely distributed throughout the brain and have traditionally been seen as caretakers that keep neural circuits stable. The new work suggests they can also shape signaling in the amygdala, a central hub for processing threat and generating fear-related learning.

    What the researchers observed

    Using a mouse model of fear learning, scientists tracked astrocyte activity in real time with fluorescent sensors. Astrocyte signaling rose during fear conditioning and again during memory recall, then declined as fear responses weakened through extinction training.

    The team also manipulated how astrocytes communicate with nearby neurons. Enhancing astrocyte-to-neuron signaling strengthened fear expression, while dampening those signals reduced fear responses, indicating astrocytes can tune the intensity of fear memories.

    How it changes the fear circuit

    When astrocyte activity was disrupted, neurons in the amygdala had difficulty forming the typical activity patterns associated with fear. That interference also appeared to affect how defensive-response information is routed to other brain regions involved in choosing and executing behavior.

    Researchers reported effects beyond the amygdala, including changes in fear-related signaling reaching the prefrontal cortex, an area tied to decision-making and regulation of emotional responses. The results suggest astrocytes may influence how the brain decides whether a threat response is appropriate.

    Why it matters for PTSD

    PTSD and several anxiety disorders are marked by persistent, hard-to-extinguish fear memories and heightened reactions to cues that are no longer dangerous. If astrocytes help govern both the expression and the fading of fear, they could become a complementary target alongside neuron-focused approaches.

    The researchers caution that translating mouse findings to human treatments takes time, but the study reframes fear circuitry as a partnership between neurons and glia. Next steps include mapping astrocyte roles across the wider threat network, including regions that coordinate freezing and flight responses.

  • UCSF study flags FTL1 protein as a driver of brain aging, and a potential new target to restore memory

    UCSF study flags FTL1 protein as a driver of brain aging, and a potential new target to restore memory

    Aging can take a heavy toll on the hippocampus, the brain region central to learning and memory. Researchers at the University of California, San Francisco report they have identified a protein that may play an outsized role in that decline.

    In a study published in Nature Aging, the team points to FTL1, a ferritin-related protein involved in iron handling, as a key molecular change seen in older mouse hippocampus. The researchers say shifting FTL1 levels altered memory performance and the strength of neural connections in ways that tracked with age.

    A standout signal in aging brains

    To pinpoint what changes over time, scientists compared gene and protein patterns in the hippocampus of young and older mice. Among many measurements, FTL1 emerged as the most consistent difference between age groups.

    Older mice had higher FTL1 levels alongside fewer synaptic connections and worse results on cognitive tasks. The authors report that the pattern suggested more than a passive marker of aging, raising the possibility that FTL1 helps drive the process.

    What happened when FTL1 was altered

    When researchers increased FTL1 in young mice, the animals developed brain and behavioral changes resembling those seen in older mice. The hippocampus showed reduced connectivity, and performance on memory-related testing declined.

    Cell experiments offered a potential explanation: neurons pushed to make more FTL1 formed simpler structures, with fewer branching extensions needed for complex signaling. That shift, the team argues, could help explain how elevated FTL1 weakens hippocampal circuitry.

    Can memory decline be reversed?

    In older mice, lowering FTL1 was linked to improved synaptic connections and better memory test performance. Senior author Saul Villeda said, “It is truly a reversal of impairments,” emphasizing that the effect went beyond delaying decline.

    The group also reported a metabolic component, with higher FTL1 associated with slower energy use in hippocampal cells. In lab settings, boosting cellular metabolism with an experimental compound reduced the harmful effects tied to elevated FTL1, pointing to possible therapeutic angles.

    Experts caution that mouse findings do not automatically translate to human brain aging, and any treatment approach would require extensive safety and efficacy testing. Still, the UCSF team argues that targeting FTL1 or related metabolic pathways could eventually open a new route for interventions aimed at age-related cognitive decline.

  • Researchers map a brain pathway that may signal fullness: Astrocytes emerge as a new appetite control target

    Researchers map a brain pathway that may signal fullness: Astrocytes emerge as a new appetite control target

    Scientists have identified a previously underappreciated brain signaling pathway that helps the body recognize when it is time to stop eating, shifting attention from neurons alone to a broader cellular network. The work, published April 6, 2026 in Proceedings of the National Academy of Sciences, focuses on how the hypothalamus processes post-meal fuel signals.

    The study centers on astrocytes, abundant brain cells long viewed mainly as support for neurons, and suggests they can actively shape appetite control. Researchers say this mechanism could eventually inform new strategies for obesity and eating-disorder treatments, though the findings are based on animal experiments.

    How glucose signals reach the brain

    After a meal, glucose levels rise and are sensed in part by tanycytes, specialized cells that line fluid-filled spaces in the brain. In the experiments, tanycytes responded to glucose by producing lactate, a metabolic byproduct that can function as a signaling molecule in the surrounding tissue.

    For years, lactate was often discussed as a signal that could act directly on appetite-regulating neurons. This research argues the message commonly takes an additional step, with astrocytes serving as a crucial intermediary before neurons that promote satiety are engaged.

    Astrocytes as appetite messengers

    The team found that astrocytes detect lactate via a receptor known as HCAR1 and, once activated, can release glutamate to influence nearby neurons. In this model, that astrocyte-to-neuron signal increases the excitability of POMC neurons, a population associated with suppressing appetite.

    In closely observed lab tests, stimulating glucose handling in a single tanycyte led to broader astrocyte activity nearby, suggesting the signal can spread through a local network. The researchers also described evidence consistent with a dual effect in the hypothalamus, potentially supporting satiety pathways while dampening hunger-promoting activity through separate routes.

    What this means for obesity research

    Because tanycytes and astrocytes exist across mammals, the authors argue the same kind of circuitry could plausibly operate in humans, but that remains to be confirmed. The next step, they say, is testing whether changing HCAR1 activity in astrocytes can reliably alter eating behavior.

    No approved drugs currently target this exact astrocyte pathway, and translating such findings into therapies typically requires years of follow-up work. Still, the researchers suggest that aiming at astrocyte signaling could one day complement existing anti-obesity approaches rather than replace them.

    The project reflects a long-running collaboration between the University of Concepción in Chile and the University of Maryland. The authors report the work was supported by Chilean research funding programs and the U.S. National Institutes of Health.

  • Johns Hopkins study spotlights hydrogen sulfide signaling as a potential new target in Alzheimer’s research

    Johns Hopkins study spotlights hydrogen sulfide signaling as a potential new target in Alzheimer’s research

    Researchers at Johns Hopkins Medicine report that a newly funded study by the National Institutes of Health is helping advance a potential new approach to Alzheimer’s disease treatment. The focus is a protein in the brain that produces a small but important gas.

    The protein, called Cystathionine γ-lyase, or CSE — best known for generating hydrogen sulfide, the gas that smells like rotten eggs — appears to play a key role in how memory forms. The findings come from experiments in genetically engineered mice, according to study leader Bindu Paul, M.S., Ph.D., associate professor of pharmacology, psychiatry and neuroscience at the Johns Hopkins University School of Medicine.

    The research, published in Proceedings of the National Academy of Sciences, aims to better understand how this protein works and whether boosting its activity could help protect brain cells and slow neurodegenerative diseases such as Alzheimer’s.

    Hydrogen Sulfide May Protect Brain Cells

    Earlier studies suggested that hydrogen sulfide can help protect neurons in mice. However, the gas is toxic in large amounts, which makes it unsafe to deliver directly to the brain. Scientists are instead trying to understand how to safely maintain the extremely small levels naturally present in neurons.

    The new findings show that mice engineered to lack the CSE enzyme develop problems with memory and learning. These mice also show increased oxidative stress, DNA damage and weakened blood-brain barrier integrity — all features commonly associated with Alzheimer’s disease, says Paul, the study’s corresponding author.

    Building on Years of Research

    The current work builds on earlier research led by Solomon Snyder, M.D., D.Sc., D.Phil., professor emeritus of neuroscience, pharmacology, and psychiatry. In 2014, his team reported that CSE supported brain health in mice with Huntington’s disease. The researchers used mice lacking the CSE protein, first developed in 2008 when the protein was linked to blood vessel function and blood pressure regulation.

    In 2021, the group found that CSE was not functioning properly in mice with Alzheimer’s disease, and that very small injections of hydrogen sulfide helped protect brain function.

    Those earlier studies focused on mice with additional genetic mutations tied to neurodegenerative diseases. The latest research isolates the role of CSE itself.

    “This most recent work indicates that CSE alone is a major player in cognitive function and could provide a new avenue for treatment pathways in Alzheimer’s disease,” says co-corresponding author Snyder, who retired from the Johns Hopkins Medicine faculty in 2023.

    Memory Loss Linked to CSE Deficiency

    To better understand how CSE affects memory, scientists compared mice lacking the protein with normal mice using the same strain developed in 2008. They tested spatial memory (ability to remember directions and follow cues) using a setup called the Barnes maze.

    In this test, mice learn to escape a bright light by finding a hidden shelter. At two months old, both normal mice and those lacking CSE performed similarly, locating the shelter within three minutes. By six months, however, the CSE-deficient mice struggled to find the escape route, while normal mice continued to succeed.

    “The decline in spatial memory indicates a progressive onset of neurodegenerative disease that we can attribute to CSE loss,” says first author Suwarna Chakraborty, a researcher in Paul’s lab.

    Brain Changes Mirror Alzheimer’s Disease

    The researchers also examined how the absence of CSE affects the brain at a cellular level. The hippocampus, a region critical for learning and memory, relies on the formation of new neurons. Disruptions in this process are a known feature of neurodegenerative diseases.

    Using biochemical and analytical methods, the team found that proteins involved in neurogenesis were reduced or missing in mice without CSE.

    With high powered electron microscopes, the scientists observed structural damage in the brains of these mice. They found large breaks in blood vessels, indicating harm to the blood-brain barrier, another hallmark of Alzheimer’s disease. In addition, newly formed neurons had difficulty reaching the hippocampus, where they normally contribute to memory formation.

    “The mice lacking CSE were compromised at multiple levels, which correlated with symptoms that we see in Alzheimer’s disease,” says co-first author Sunil Jamuna Tripathi, a researcher in Paul’s lab.

    Toward New Alzheimer’s Treatments

    Alzheimer’s disease affects more than 6 million people in the United States, according to the U.S. Centers for Disease Control and Prevention, and the number continues to grow. Currently, no treatments have been consistently shown to stop or slow the disease.

    The researchers say that targeting CSE and its production of hydrogen sulfide could offer a new path for developing therapies aimed at protecting brain function and slowing disease progression.

    Funding and Research Contributors

    Funding support for this research was provided by the National Institutes of Health (1R01AG071512, P50 DA044123,1R21AG073684, O1AGs066707, U01 AG073323, AG077396, NS101967, NS133688, P01CA236778), the Department of Defense (HT94252310443), the American Heart Association, AHA-Allen Initiative in Brain Health and Cognitive Impairment, the Solve ME/CFS Initiative, the Catalyst Award from Johns Hopkins University, the Valour Foundation, the Wick Foundation, Department of Veterans Affairs Merit Award (I01BX005976), the Louis Stokes Cleveland Department of Medical Affairs Veterans Center, the Mary Alice Smith Funds for Neuropsychiatry Research, the Lincoln Neurotherapeutics Research Fund, the Gordon and Evie Safran Neuropsychiatry Fund; and the Leonard Krieger Fund of the Cleveland Foundation.

    In addition to Paul, Snyder, Chakraborty and Tripathi, contributors included Richa Tyagi and Benjamin Orsburn from Johns Hopkins; Edwin Vázquez-Rosa, Kalyani Chaubey, Hisashi Fujioka, Emiko Miller and Andrew Pieper of Case Western University; Thibaut Vignane and Milos Filipovic from Leibniz Institute for Analytical Sciences, Germany; Sudarshana Sharma from Hollings Cancer Center; Bobby Thomas from Darby Children’s Research Institute and the Medical University of South Carolina, and Zachary Weil and Randy Nelson from West Virginia University School of Medicine.

  • Depression research takes a new turn: Scientists trace the disorder to specific brain cell types

    Depression research takes a new turn: Scientists trace the disorder to specific brain cell types

    Scientists at McGill University and the Douglas Research Centre have identified specific brain cell types that show altered activity in people with major depression, a finding that could help sharpen the search for more targeted treatments.

    The work, published in Nature Genetics, combines genetic risk signals with cell-level measurements from human brain tissue to pinpoint where depression-related changes appear most strongly.

    Depression is among the world’s leading causes of disability, and many patients do not respond fully to existing therapies. Researchers have long suspected that depression involves measurable biological changes, but mapping them to precise cell types has been difficult.

    Rare brain tissue, sharper tools

    The team relied on post-mortem samples from the Douglas-Bell Canada Brain Bank, one of the specialized collections that includes tissue from people diagnosed with psychiatric conditions.

    Using single-nucleus methods, the researchers profiled gene regulation and gene activity across thousands of individual cells, comparing samples from 59 people with depression and 41 without it.

    Neurons and microglia stand out

    The analysis highlighted two cell populations with notable differences in depression: a group of excitatory neurons involved in mood and stress-related circuits, and a subtype of microglia, immune cells that help regulate inflammation in the brain.

    In both cell types, multiple genes showed altered patterns of activity, suggesting that disruptions in neural signaling and immune-related pathways may converge in the disorder.

    What this could mean for treatment

    By tying depression-associated genetic mechanisms to defined cell types, the study offers a clearer roadmap for experiments that test how these cellular shifts affect brain function over time.

    Researchers caution that the findings do not translate directly into an immediate new therapy, but they may help guide drug development and biomarker research toward more precise biological targets.

    Senior author Gustavo Turecki said the approach provides a clearer picture of where disruptions occur and which cells are involved, reinforcing the view that depression reflects identifiable brain changes rather than a purely psychological experience.

  • Harvard study traces a gut bacteria link to depression, pointing to an environmental chemical that may fuel inflammation

    Harvard study traces a gut bacteria link to depression, pointing to an environmental chemical that may fuel inflammation

    Harvard Medical School researchers have outlined a new molecular pathway that may help explain why certain gut bacteria are repeatedly associated with major depressive disorder. The work centers on Morganella morganii and an immune reaction that could connect gut chemistry to brain health.

    In the study, scientists found that an environmental contaminant called diethanolamine, or DEA, can be incorporated into a lipid-like molecule produced by M. morganii in the gut. That altered molecule appears to behave differently than the standard version, shifting from relatively inert to immune-activating.

    A chemical swap with immune effects

    Laboratory tests showed the modified bacterial molecule can stimulate inflammatory signaling, including elevated release of cytokines such as interleukin-6, or IL-6. IL-6 has been widely studied as part of the broader link between inflammation and depressive symptoms in some patients.

    The authors argue this provides a clearer mechanism than earlier correlation-based microbiome findings, though it does not prove the pathway causes depression in humans. They say additional clinical work is needed to determine how often this chemistry occurs in real-world conditions and who may be most affected.

    Why inflammation matters in depression

    Inflammation has long been investigated as one contributor to depression, with evidence suggesting a subset of cases may involve immune dysregulation. The new results fit into that view by describing how a bacterial product, altered by exposure to a common industrial chemical, might intensify inflammatory signaling.

    The team also notes that M. morganii has been associated in prior research with inflammatory conditions beyond depression, including metabolic and gastrointestinal diseases. That pattern, they say, supports the idea that the bacterium’s metabolites can interact with the immune system in clinically meaningful ways.

    Potential paths for diagnosis and treatment

    The researchers suggest DEA-related chemistry could eventually help identify biological subtypes of depression, potentially using exposure markers or microbial metabolites as part of a diagnostic approach. Any such use would require validation in human cohorts and careful separation of correlation from causation.

    More broadly, the findings add momentum to efforts exploring treatments that target inflammation for selected patients, alongside established psychological and pharmacological therapies. The authors describe their work as a framework for scanning other gut microbes for similar pollutant-driven metabolic changes.

    The study was published in the Journal of the American Chemical Society and combined expertise in bacterial small-molecule chemistry and microbiome-immunity interactions. Researchers involved also highlighted the role of cross-disciplinary microbiome research in moving from broad associations toward specific, testable mechanisms.